← Back to Home

Activation Only When Both Markers Are Present: VERAXA Explores Dual Recognition in Cancer Treatment

Getting antibodies to recognize cancer cells is not enough to prevent unintended damage. VERAXA splits treatment into two complementary components to test a dual-marker activation strategy in cell and mouse studies; whether this can provide the safety margin needed in humans still awaits clinical validation.

By SURL BioNews

Markers on the surface of cancer cells can often also be found in healthy tissues. This poses a challenge for precision cancer treatment: even when a drug recognizes the correct target, it may still harm normal cells. The BiTAC platform being explored by VERAXA Biotech seeks to add another condition before an attack can begin—two specified markers must be recognized on the same cell before the cell-killing function is activated.

This concept was the central theme of a September financial article introducing VERAXA’s research and development strategy. Its experimental basis includes material presented at the American Association for Cancer Research (AACR) annual meeting in April and antibody-drug conjugate research announced by the company in June. The two approaches use immune cells and cytotoxic drugs, respectively, but share a common principle: splitting treatment into complementary components so that dual recognition determines where it acts.

In the T-cell engager (TCE) approach, two precursor molecules each retain the ability to recognize a tumor marker, but neither can effectively bind CD3 on the surface of T cells on its own. According to the company’s technical description, the CD3-binding function is reconstituted only when both molecules bind their corresponding markers on the same cell, recruiting T cells to attack. This “AND logic gate” design aims to spare healthy cells that carry only one of the two markers.

AACR 2026 abstract No. 1634 reported that, in two-dimensional and three-dimensional culture models, BiTAC-TCE selectively killed cells carrying both markers while sparing cells carrying only one marker; it also showed antitumor activity in mice bearing human immune cells and colorectal tumors. The abstract also stated that lead programs targeting colorectal cancer and lung cancer had, at the time, entered formal preclinical development and studies supporting applications for human trials. These results support the design principle but do not yet demonstrate that patients will benefit.

The other approach, BiTAC-ADC, uses two antibodies to separately deliver an inactive prodrug and a precursor activating component that cannot cross cell membranes on its own. Under the design announced by the company on June 18, cytotoxicity is generated only after both components are taken up by the same cancer cell. The company said that in vitro experiments had distinguished breast cancer cells from healthy cells and that killing increased with dose in three-dimensional tumor spheroids; the announcement provides early proof of concept.

Dual recognition also brings new validation requirements: Do patients’ tumors consistently express both markers at the same time? Can the two components reach the same cell in the appropriate ratio? Do healthy tissues contain combinations of markers sufficient to trigger the response? These questions must be answered when moving from experimental models into humans. Conference abstracts and company announcements are also insufficient to fully assess long-term toxicity and differences among patients.

BiTAC’s appeal lies in advancing precision from “which target is recognized” to “which conditions must be met simultaneously before action is taken.” Current data provide preclinical support for this concept, but increasing usable doses and widening the therapeutic window remain goals that require validation. The real test is whether this dual-recognition mechanism can preserve both anticancer activity and healthy tissues once it enters humans.

References

  1. Yahoo Finance
  2. VERAXA Biotech
  3. American Association for Cancer Research
  4. VERAXA Biotech